Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 915 of 2183 results for guidelines

  1. The EQ-5D-5L

    The EQ-5D is a short questionnaire used to understand how a person’s health affects their quality of life. It is used in health research and to help inform decisions about healthcare treatments.

  2. Diabetes: blood pressure (without moderate or severe frailty) (IND249)

    This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233

  3. New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (HTG281)

    Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.

  4. Artificial intelligence (AI) at NICE

    reporting indicate existing regulations, good practices, standards and guidelines to follow when using AI methods, where appropriate...

  5. Monitoring and follow-up for adults with hearing loss:- What is the clinical and cost effectiveness of monitoring and follow-up for adults with hearing loss post-intervention compared with usual care?

    applicable) Why this is important:- The evidence review for the NICE guideline on hearing loss found a lack of evidence to establish the...

  6. GPs and primary care

    GPs help to bring a primary care perspective to the guidance that we produce.

  7. GPs and primary care

    GPs help to bring a primary care perspective to the guidance that we produce.

  8. SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea (MIB190)

    NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .

  9. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  10. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  11. Technology appraisal data: appraisal recommendations

    Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  12. HIV: routine blood tests (IND211)

    This indicator covers the percentage of adults and young people at a GP surgery in an area of high or extremely high HIV prevalence who have not had an HIV test in the last 12 months, who are having a blood test and receive an HIV test at the same time. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM190

  13. HIV: testing at registration (IND210)

    This indicator covers the percentage of adults and young people newly registered with a GP in an area of high or extremely high HIV prevalence who receive an HIV test within 3 months of registration. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM189

  14. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

  15. The geko device for reducing the risk of venous thromboembolism (HTG344)

    Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.